Drug Interactions Database

3916 interactions from BNF 85 - Check your medicines

Source: BNF 85
eltrombopag larotrectinib

increases exposure

Unknown Study
eltrombopag letermovir

increases concentration

Unknown Study
eltrombopag methotrexate

increases concentration

Unknown Theoretical
eltrombopag talazoparib

increases exposure

Unknown Theoretical
eltrombopag tenofoviralafenamide

increases exposure

Unknown Theoretical
eltrombopag tenofovirdisoproxil

increases exposure

Unknown Theoretical
eltrombopag venetoclax

increases exposure

Unknown Theoretical
elvitegravir coumarins

decreases anticoagulant effect

Unknown Anecdotal
elvitegravir grazoprevir

increases exposure

Unknown Study
encorafenib combinedhormonalcontraceptives

affects exposure

Unknown Theoretical
encorafenib dolutegravir

increases exposure

Unknown Theoretical
encorafenib raltegravir

increases exposure

Unknown Theoretical
encorafenib theactivecomponentofsacituzumabgovitecan

increases exposure

Unknown Theoretical
entacapone adrenalineepinephrine

increases risk of cardiovascularadverseeffects

Unknown Study
entacapone methyldopa

increases exposure

Unknown Theoretical
entacapone noradrenalinenorepinephrine

increases risk of cardiovascularadverseeffects

Unknown Study
entacapone sympathomimetics,inotropic

increases risk of cardiovascularadverseeffects

Unknown Theoretical
entacapone sympathomimetics,vasoconstrictor

increases risk of cardiovascularadverseeffects

Unknown Study
entrectinib alfentanil

increases exposure

Unknown Theoretical
entrectinib benzodiazepines

increases exposure

Unknown Study
entrectinib ciclosporin

increases exposure

Unknown Theoretical
entrectinib ergotamine

increases exposure

Unknown Theoretical
entrectinib everolimus

increases exposure

Unknown Theoretical
entrectinib fentanyl

increases exposure

Unknown Theoretical
entrectinib midazolam

increases exposure

Unknown Study
entrectinib opioids

increases exposure

Unknown Theoretical
entrectinib sirolimus

increases exposure

Unknown Theoretical
entrectinib temsirolimus

increases exposure

Unknown Theoretical
enzalutamide antiepileptics

decreases exposure

Unknown Theoretical
enzalutamide antipsychotics,secondgeneration

decreases exposure

Unknown Theoretical
enzalutamide atorvastatin

decreases exposure

Unknown Study
enzalutamide avatrombopag

decreases exposure

Unknown Study
enzalutamide brivaracetam

decreases exposure

Unknown Theoretical
enzalutamide clozapine

decreases exposure

Unknown Theoretical
enzalutamide diltiazem

decreases exposure

Unknown Study
enzalutamide simvastatin

decreases exposure

Unknown Study
enzalutamide statins

decreases exposure

Unknown Study
enzalutamide ulipristal

decreases efficacy

Unknown Theoretical
enzalutamide verapamil

decreases exposure

Unknown Study
eplerenone lithium

increases concentration

Unknown Theoretical
eplerenonevery digoxin

increases exposure

Unknown Study
ergometrine noradrenaline

increases risk of peripheralvasoconstriction

Unknown Anecdotal
ergometrine noradrenalinenorepinephrine

increases risk of peripheralvasoconstriction

Unknown Anecdotal
ergometrine sympathomimetics,vasoconstrictor

increases risk of peripheralvasoconstriction

Unknown Anecdotal
erlotinib aspirin

increases risk of gastrointestinalperforation

Unknown Theoretical
erlotinib corticosteroids

increases risk of gastrointestinalperforation

Unknown Theoretical
erlotinib coumarins

increases anticoagulant effect

Unknown Anecdotal
erlotinib high-dose

increases risk of gastrointestinalperforation

Unknown Theoretical
erlotinib phenindione

increases risk of bleedingevents

Unknown Theoretical
erlotinib theactivecomponentofsacituzumabgovitecan

increases exposure

Unknown Theoretical
Important: This database uses data from the British National Formulary (BNF 85). It is for informational purposes only and is not a substitute for professional medical advice.